

ADVANCED COURSE PROGRAMME

Prostate Cancer

**ESMO VIRTUAL
ADVANCED COURSE**

**ONLINE
30-31 MARCH 2022**

Chairs:

Elena Castro, Spain
Fabio Schütz, Brazil

ESMO VIRTUAL ADVANCED COURSE PROGRAMME CLINICAL QUESTIONS IN PROSTATE CANCER

30-31 March 2022

CO-CHAIRS: Elena Castro, Spain
Fabio Schütz, Brazil

SPEAKERS: Maria Teresa Bourlon, Mexico
Stefano Fanti, Italy
Valérie Fonteyne, Belgium
Pernelle Lavaud, France
Murilo Luz, Brazil
Ray Manneh, Colombia
Juan Pablo Sade, Argentina
Rafael Sanchez Salas, Canada

LEARNING OBJECTIVES

- To understand essentials in the assessment and the value of multidisciplinary management of prostate cancer
- To learn about state-of-the-art advances in treatment of prostate cancer
- To learn the principles of management of advanced prostate cancer through direct exposure to real clinical scenarios

ACCREDITATION

The programme of this virtual event has been accredited with **6 ESMO-MORA category 1 points**.

Recertification is necessary for medical oncologists to remain professionally certified by ESMO. Recertification guarantees that a certified medical oncologist has continued to update his/her knowledge and continues to possess the necessary skills and standards for the practice of medical oncology. For further details please refer to esmo.org

ACKNOWLEDGEMENTS

This event is supported by an unrestricted educational grant from



ORGANISATION AND CONTACTS

ESMO Head Office
Education Department
Via Ginevra 4
6900 Lugano
Switzerland
Email: courses@esmo.org
www.esmo.org



All timings are to be considered CEST (Central European Summer Time)

Wednesday, 30 March 2022

15:30-15:35 **Welcome and course overview**

5' Elena Castro, ES
Fabio Schütz, BR

15:35-16:15 **Session 1**
State-of-the-art in prostate cancer diagnostics

15' PSMA based diagnostics: The future of imaging
Stefano Fanti, IT

15' Biology: Clinical genomics in prostate cancer management
Elena Castro, ES

10' Discussion
Faculty

16:15-16:55 **Session 2**
High risk localized prostate cancer

15' Role of radiotherapy: Recent advances in RT modalities (*including hypofractionation, brachytherapy, SABR*)
Valérie Fonteyne, BE

15' High risk localized disease: Integrating drugs with local treatments
Murilo Luz, BR

10' Discussion
Faculty

16:55-17:10 **Break**

17:10-18:05 **Session 3**
Intermediate situation of advanced prostate cancer

15' Rising PSA: biochemical recurrence management
Rafael Sanchez Salas, CA

15' Oligometastatic prostate cancer
Valérie Fonteyne, BE

15' M0 Castrate Resistant Prostate Cancer (CRPC): What are our latest options?
Juan Pablo Sade, AR

10' Discussion
Faculty

18:05–18:45	Session 4 Metastatic prostate cancer – Part 1
15'	Metastatic hormone sensitive prostate cancer: State of the art management in 2022 Fabio Schütz, BR
15'	Metastatic CRPC: Standard of care in 2022 (<i>including bone targeting agents</i>) Ray Manneh, CO
10'	Discussion Faculty

Thursday, 31 March 2022

15:30–16:10	Session 5 Metastatic prostate cancer – Part 2
15'	Metastatic CRPC: What's on the horizon – new treatments (targeted therapies, PARP inhibitors) Maria Teresa Bourslon, MX
15'	Metastatic CRPC: What's on the horizon – new treatments (immunotherapy, BiTE and others) Pernelle Lavaud, FR
10'	Discussion Faculty
16:10–19:00	Workshops sessions Three workshops sessions 10' Introduction based on clinical cases presented by speakers 30' Discussion
Workshop 1 60'	Localized prostate cancer Valérie Fonteyne, BE Rafael Sanchez Salas, CA
17:10– 17:25	Break
Workshop 2 60'	High risk/locally advanced prostate cancer Murilo Luz, BR Juan Pablo Sade, AR
Workshop 3 30'	Metastatic prostate cancer Pernelle Lavaud, FR
18:55–19:00	Conclusion and farewell Elena Castro, ES Fabio Schütz, BR